27-Hydroxycholesterol induces the transition of MCF7 cells into a mesenchymal phenotype

Oncology Reports

Volumn 26, Issue 2, 2011, Pages 389-397

  Torres, Cristian G ^a   Ramí Rez, María E ^b   Cruz, Pamela ^b   Epuñan, María J ^b   Valladares, Luis E ^b   Sierralta, Walter D ^b  

^a UNIVERSIDAD ANDRÉS BELLO   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

catenin; 27 hydroxycholesterol; Adherens junction; E cadherin; Epidermal growth factor receptor 2 neu; Human mammary cancer; MCF7 cells

Indexed keywords

26 HYDROXYCHOLESTEROL; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; OXYSTEROL; UVOMORULIN;

ARTICLE; CANCER INVASION; CELL GROWTH; CELL JUNCTION; CELL MEMBRANE; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION;

ADHERENS JUNCTIONS; ANIMALS; BETA CATENIN; BREAST NEOPLASMS; CADHERINS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; ESTRADIOL; FEMALE; HUMANS; HYDROXYCHOLESTEROLS; PHENOTYPE;

EID: 79958238550     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1284     Document Type: Article

References (39)

1. Russo IH and Russo J: Pole of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3: 49-61, 1998. (Pubitemid 128513219)
2. Conzen SD: Nuclear receptors and breast cancer. Mol Endocrinol 22: 2215-2228, 2008.
3. Shelly W, Draper MW, Krishnan V, Wong M and Jaffe RB: Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 63: 163-181, 2008. (Pubitemid 351612435)
4. Fox EM, Andrade J and Shupnik MA: Novel actions of estrogen to promote proliferation integration of cytoplasmic and nuclear pathways. Steroids 74: 622-627, 2009.
5. Madak-Erdogan Z, Kieser KJ, Kim SH, Komm B, Katzenellenbogen JA and Katzenellenbogen BS: Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol Endocrinol 22: 2116-2127, 2008.
6. Hall JM and McDonnell DP: Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv 5: 343-357, 2005. (Pubitemid 43060715)
7. Sasano H, Suzuki T, Nakata T and Moriya T: New development in intracrinology of breast carcinoma. Breast Cancer 13: 129-136, 2006.
8. Spears M and Bartlett J: The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer. Expert Opin Ther Targets. 13: 665-674, 2009.
9. Arpino G, Weichmann L, Osborne CK and Schiff R: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217-233, 2008. (Pubitemid 351519691)
10. Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB, Korach KS, Shaul PW and Mangelsdorf DJ: 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogens. Nat Med 13: 1185-1192, 2007. (Pubitemid 47530633)
11. DuSell CD, Nelson ER, Wing X, Abdo J, Mödder UI, Umetani M, Gesty-Palmer D, Javitt NB, Khosla S and McDonnell DP: The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology 151: 3675-3685, 2010.
12. DuSell CD, Umetani M, Shaul PW, Mangelsdorf DJ and McDonnell DP: 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol 22: 65-77, 2008.
13. Cruz P, Torres C, Ramírez ME, Epuñán MJ, Valladares LE and Sierralta WD: Proliferation of human mammary cancer cells exposed to 27-hydroxycholesterol. Exp Ther Med 1: 531-536, 2010.
14. Micalizzi DS, Farabaugh SM and Ford HL: Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 15: 117-134, 2010.
15. Hirayama T, Mizokami Y, Honda A, Homma Y, Ikegami T, Saito Y, Miyazaki T and Matsuzaki Y: Serum concentration of 27-hydroxycholesterol predicts the effects of high-cholesterol diet on plasma LDL cholesterol level. Hepatol Res 39: 149-156, 2009.
16. DuSell CD and McDonnell DP: 27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling. Trends Pharmacol Sci 29: 510-514, 2008.
17. Dickson RB, Bates SE, McManaway ME and Lippman ME: Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res 46: 1707-1713, 1986. (Pubitemid 16121496)
18. Foldynová-Trantírková S, Sekyrová Petra, Tmejová K, Brumovská E, Bernatík O, Blankenfeldt W, Krejčí P, Kozubík A, Doležal T, Trantírek L and Bryja V: Breast cancer-specific mutations in CK1ε inhibit Wnt/β-catenin and activate the Wnt/ Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration. Breast Cancer Res 12: R30, 2010.
19. Brown AJ and Jessup W: Oxysterols and atherosclerosis. Atherosclerosis 142: 1-28, 1999. (Pubitemid 28553934)
20. Babiker A, Dzeletovic S, Wiklund B, Pettersson N, Salonen J, Nyyssönen K, Eriksson M, Diczfalusy U and Björkhem I: Patients with atherosclerosis may have increased circulating levels of 27-hydroxycholesterol and cholestenoic acid. Scand J Clin Lab Invest 65: 365-375, 2005.
21. Olkkonen VM and Hynynen R: Interactions of oxysterols with membranes and proteins. Mol Aspects Med 30: 123-133, 2009.
22. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000. (Pubitemid 30046295)
23. Zhu Y, Nilsson M and Sundfeldt K: Phenotypic plasticity of the ovarian surface epithelium: TGF-β1 induction of epithelial to mesenchymal transition (EMT) in vitro. Endocrinology 151: 5497-5505, 2010.
24. Li Y, Wang JP, Santen RJ, Kim TH, Park H, Fan P and Yue W: Estrogen stimulation of cell migration involves multiple signaling pathway interactions. Endocrinology 151: 5146-5156, 2010.
25. Acconcia F, Barnes CJ and Kumar R: Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology 147: 1203-1212, 2006. (Pubitemid 43244353)
26. Sanchez AM, Flamini MI, Baldacci Ch, Goglia L, Genazzani AR and Simoncin T: Estrogen receptor-α promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol 24: 2114-2125, 2010.
27. Moustakas A and Heldin C-H: Signaling networks guiding epithelial-mesenchymal transitions during embrysgenesis and cancer progression. Cancer Sci 98: 1512-1520, 2007. (Pubitemid 47308444)
28. Muller T Bain G, Wang X and Papkoff J: Regulation of epithelial migration and tumor formation by β-catenin signalling. Exp Cell Res 280: 119-133, 2002. (Pubitemid 35230373)
29. Roura S, Miravet S, Piedra J, García de Herreros A and Dunach M: Regulation of E-cadherin/catenin association by tyrosine phosphorylation. J Biol Chem 274: 36734-36740, 1999.
30. Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B and Gendler SJ: ErbB-β-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-neu transgenic carcinomas J Biol Chem 277: 22692-22698, 2002. (Pubitemid 34967248)
31. Jeanes A, Gottardi CJ and Yap AS: Cadherins and cancer: How does cadherin dysfunction promote tumor progression? Oncogene 27: 6920-6929, 2008.
32. Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D and Nicholson RI: Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation. Int J Cancer 118: 290-301, 2006. (Pubitemid 41779067)
33. Calle EE and Thun MJ: Obesity and cancer. Oncogene 23: 6365-6378, 2004. (Pubitemid 39265505)
34. Brueggemeier RW, Hackett JC and Diaz-Cruz ES: Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 26: 331-345, 2005. (Pubitemid 40686647)
35. Brodie A: Aromatase inhibitors in breast cancer. Trends Endocrinol Metab 13: 61-65, 2002.
36. Miyoshi Y, Murase K, Saito M and Oh K: Prediction of hormone sensitivity for breast cancers. Breast Cancer 17: 86-91, 2010.
37. Lange Y, Steck TL, Ye J, Lanier MH, Molugu V and Ory D: Regulation of fibroblast mitochondrial 27-hydroxycholesterol production by active plasma membrane cholesterol. J Lipid Res 50: 1881-1888, 2009.
38. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, Paskett ED, Vitolins MZ, Furberg CD and Chlebowski RT: Statin use and breast cancer: prospective results from the women's health initiative. J Natl Cancer Inst 98: 700-707, 2006. (Pubitemid 43821787)
39. Culhane AC and Howlin J: Molecular profiling of breast cancer: transcriptomic studies and beyond. Cell Mol Life Sci 64: 3185-3200, 2007.